Investor Relations
Key Figures
| IFRS (in EURm except otherwise stated) | 2017 | 2016 |
| Revenues | 2,971.4 | 2,536.6 |
| Adjusted EBITDA | 556.7 | 479.6 |
| Reported EBITDA | 513.2 | 461.1 |
| Basic EPS (EUR) | 12.68 | 10.88 |
| Net Operating Cash Flow | 405.1 | 371.8 |
Outstanding shares:
17,676,219 (at 30.04.2018)
Dividend
The AGM of 20 April 2017 approved the payment of a dividend of EUR 2.00 per share for the year 2016 compared to EUR 1.45 for the previous year.
Financial News
- 23.05.2018Eurofins announces the inauguration of its newly-upgraded and expanded state-of-the-art food testing laboratory in Suzhou, China
- 22.05.2018Eurofins expands its biopharmaceutical products testing footprint with an outsourcing agreement with Astellas in Japan
- 09.05.2018Eurofins expands its leadership in biopharmaceutical services with the acquisition of PHAST in Germany
- 30.04.2018Eurofins to expand its presence in North America, the United Kingdom and Asia with the acquisition of LabCorp’s food testing and consulting business
- 24.04.2018Eurofins revenues grow +23% in Q1 2018 to EUR 839m
Annual Reports
Next Publication: Q1 2018 Interim Management Statement, 24 April 2018 (TBC)
Order a hard copy of the 2017 Annual Report
Eurofins' 20-year IPO value creation study by Marten & Co.
Research Paper by Prof. Brooks
OBSAAR prospectus in French only
